Table 1. Baseline demographics and clinical characteristics.
| Characteristic | Part An=46 | Part Bn=74 | Part Cn=166 |
| Age, years, median (range) | 60 (35–82) | 67 (37–82) | 62 (24–85) |
| Sex | |||
| Male | 27 (59) | 49 (66) | 85 (51) |
| Female | 19 (41) | 25 (34) | 81 (49) |
| Race | |||
| White | 41 (89) | 67 (91) | 142 (86) |
| Black or African American | 4 (9) | 1 (1) | 15 (9) |
| Asian | 0 | 6 (8) | 3 (2) |
| Other | 1 (2) | 0 | 5 (3) |
| ECOG performance status | |||
| 0 | 18 (39) | 30 (40) | 53 (32) |
| 1 | 28 (61) | 44 (60) | 113 (68) |
| Previous lines of therapy, median (range) | 3 (1–8) | 2 (1–8) | 3 (1–9) |
| Primary tumor type | |||
| Melanoma | 10 (22) | 47 (64) | 30 (18) |
| Non-small-cell lung cancer | 0 | 0 | 29 (18) |
| Ovarian | 2 (4) | 0 | 17 (10) |
| Colorectal cancer | 0 | 0 | 13 (8) |
| Renal cell carcinoma | 6 (13) | 27 (36) | 12 (7) |
| Small-cell lung cancer | 0 | 0 | 8 (5) |
| Bladder cancer | 0 | 0 | 7 (4) |
| Head and neck cancer | 0 | 0 | 7 (4) |
| Cervical cancer | 0 | 0 | 6 (4) |
| Breast cancer | 1 (2) | 0 | 6 (4) |
| Sarcoma | 2 (4) | 0 | 6 (4) |
| Esophageal cancer | 2 (4) | 0 | 4 (2) |
| Pancreatic cancer | 4 (9) | 0 | 2 (1) |
| Uterine | 1 (2) | 0 | 1 (1) |
| Gastric | 1 (2) | 0 | 1 (1) |
| Other | 17 (37) | 0 | 17 (10) |
Data are presented as number of patients (%) unless otherwise noted. ICI, immune checkpoint inhibitor;ECOG, .
ECOGEastern Cooperative Oncology GroupICIimmune checkpoint inhibitor